Skip to content

Comparison the effect of propofol with subcutaneous Sumatriptane in treatment of acute migraine headache

Comparison the effect of propofol with subcutaneous Sumatriptane in treatment of acute migraine headache

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201008174583N1
Enrollment
90
Registered
2012-08-19
Start date
2012-03-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura [common mMigrain)migrane with aura [classical migraine]igraine],

Interventions

Intervention 1: In intervention group after starting an IV line 2 cc of normal saline is injected sub-subcutaneously and then 3 cc of Propofol is prescribed as bolus and then 1 to 2 cc of 1% is admini
Treatment - Drugs
In intervention group after starting an IV line 2 cc of normal saline is injected sub-subcutaneously and then 3 cc of Propofol is prescribed as bolus and then 1 to 2 cc of 1% is administered every 3 t
In control group after starting an IV line 6 mg of Somatriptane is injected subcutaneously and then 3cc of normal saline is injected as bolus and then 1to 2 cc every 3 to 5 minutes maximally up to 12

Sponsors

Shahid Sadoughi University of Medical Sciences-Yazd, Iran
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients aged between 18 and 45 years old with acute migraine headache admitted in emergency department or pain clinic. exclusion criteria are pregnancy; opium addiction; diastolic pressure greater than 105. Sign and symptoms of organic headache peripheral and coronary artery disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Headache severity. Timepoint: Before intervention; half an hour; one hour; and 2 hours after intervention. Method of measurement: Visual Analog Scale(VAS).

Secondary

MeasureTime frame
Accompanying symptoms including nausea vomiting photophobia and phonophobia. Timepoint: Before, half an hour, and one hour after intervention. Method of measurement: Observation.;Drug side effects including hypotension; bradycardia; nausea; vertigo; paresthesia. Timepoint: After intervention. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Hossein Moshtaghion

Shahid Sadoughi University of Medical Sciences-Yazd, Iran

moshtaghion@gmail.com+98 35 1525 0207

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026